XML 50 R35.htm IDEA: XBRL DOCUMENT v3.25.2
Revenues (Tables)
 6 Months Ended
Jun. 30, 2025
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
The following table presents a summary of total revenues (in thousands): 
Three Months Ended
June 30,		Six Months Ended
June 30,
2025202420252024
Xywav$415,321 $368,472 $760,125 $683,772 
Xyrem35,349 62,180 72,590 126,412 
Epidiolex/Epidyolex251,730 247,102 469,467 445,818 
Sativex4,615 6,383 10,022 9,118 
Total Neuroscience707,015 684,137 1,312,204 1,265,120 
Rylaze/Enrylaze100,659 107,829 194,892 210,579 
Zepzelca74,541 81,047 137,574 156,147 
Defitelio/defibrotide 48,106 45,421 88,768 93,097 
Vyxeos44,851 43,012 74,395 75,035 
Ziihera5,991 — 7,966 — 
Total Oncology274,148 277,309 503,595 534,858 
Other4,408 2,698 9,190 6,268 
Product sales, net985,571 964,144 1,824,989 1,806,246 
High-sodium oxybate AG royalty revenue54,138 54,164 103,084 104,111 
Other royalty and contract revenues6,003 5,517 15,480 15,451 
Total revenues$1,045,712 $1,023,825 $1,943,553 $1,925,808 

The following table presents a summary of total revenues attributed to geographic sources (in thousands): 
Three Months Ended
June 30,		Six Months Ended
June 30,
2025202420252024
United States$936,283 $924,592 $1,734,797 $1,732,806 
Europe82,763 82,159 165,801 153,514 
All other26,666 17,074 42,955 39,488 
Total revenues$1,045,712 $1,023,825 $1,943,553 $1,925,808 
Schedule of Percentage of Total Revenues from Customers
The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues: 
Three Months Ended
June 30,		Six Months Ended
June 30,
2025202420252024
ESSDS43 %42 %42 %42 %
ASD11 %10 %11 %8 %
McKesson10 %12 %11 %12 %